An Array BioPharma investor is facing insider trading allegations, with criminal and civil cases accusing him of unlawfully trading stock options after learning from his wife—an Array employee—that ...

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced today that the strategic alliance between Array and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

BOULDER, Colo. (AP) — Federal regulators say a former manager at Boulder-based Array BioPharma Inc. will pay nearly $150,000 to settle allegations of insider ...

Pfizer agreed to spend $11 billion to buy Array BioPharma, a company that is developing small molecule medicines primarily to treat cancer. Pfizer agreed to spend $11 billion to buy Array BioPharma, a ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Array BioPharma Inc. ARRY is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving ...

* Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - ‍FDA set a target action ...

April 20 (Reuters) - Array BioPharma Inc shares rose as much as 38 percent Tuesday, a day after it signed a licensing deal for its cancer drug candidates with Swiss drugmaker Novartis AG , its second ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...